Company | Cap $ | P/E | P/B | P/S | ROE | ROA | ROS | L/A | P/FCF | PR | Period |
---|---|---|---|---|---|---|---|---|---|---|---|
Red Cat Holdings | 42 | 2022 | |||||||||
Cardlytics | 130 | 2023q1 | |||||||||
Champions Oncology | 66 | 2024q2 | |||||||||
ADC Therapeutics | 121 | 2023q2 | |||||||||
GeoVax Labs | 158 | 2021 | |||||||||
Alnylam Pharmaceuticals | 33,795 | 2022 | |||||||||
Cooper-Standard Holdings | 274 | 2023 | |||||||||
Ultragenyx Pharmaceutical | 3,189 | 2023q3 | |||||||||
Sarepta Therapeutics | 11,809 | 2023q3 | |||||||||
Canopy Growth | 702 | 2024q3 | |||||||||
Axsome Therapeutics | 3,872 | 2024q2 | |||||||||
Madrigal Pharmaceuticals | 3,943 | 2023q1 | |||||||||
Zeta Global Holdings | 1,736 | 2023q3 | |||||||||
Roblox | 19,803 | 2022 | |||||||||
Marker Therapeutics | 332 | 2021 | |||||||||
Blend Labs | 1,102 | 2023q3 | |||||||||
Jumia Technologies | 403 | 2024q2 | |||||||||
CV Sciences | 4 | 2021 | |||||||||
Precigen | 275 | 2021 | |||||||||
Opendoor Technologies | 1,292 | 2023q2 |